DESIGN THERAPEUTICS INC (DSGN) Stock Analyst Ratings
USA - NASDAQ:DSGN - US25056L1035 - Common Stock
6.7 USD
+0.17 (+2.6%)
6.7 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to DSGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.48. This target is 11.64% above the current price.
DSGN was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about DSGN.
In the previous month the buy percentage consensus was at a similar level.
DSGN was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-08-06 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-05-07 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-03-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-20 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-14 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-08-15 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-08-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-08-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-05-10 | Wedbush | Maintains | Outperform |
| 2023-05-04 | Goldman Sachs | Upgrade | Sell -> Neutral |
| 2023-03-15 | RBC Capital | Reiterate | Outperform |
| 2022-12-09 | SVB Leerink | Maintains | Outperform |
| 2022-12-08 | RBC Capital | Maintains | Outperform |
| 2022-08-09 | Wedbush | Maintains | Outperform |
| 2022-06-10 | Wedbush | Initiate | Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-10 | SVB Leerink | Maintains | Outperform |
| 2022-05-02 | RBC Capital | Initiate | Outperform |
| 2022-01-19 | Goldman Sachs | Initiate | Sell |
| 2021-04-20 | SVB Leerink | Initiate | Outperform |
| 2021-04-20 | Goldman Sachs | Initiate | Neutral |
| 2021-04-20 | Piper Sandler | Initiate | Overweight |
DESIGN THERAPEUTICS INC / DSGN FAQ
What is the price target for DSGN stock?
9 analysts have analysed DSGN and the average price target is 7.48 USD. This implies a price increase of 11.64% is expected in the next year compared to the current price of 6.7.
What is the consensus rating for DESIGN THERAPEUTICS INC (DSGN) stock?
The consensus rating for DESIGN THERAPEUTICS INC (DSGN) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.